Research
Hormonal
GLP-1 agonists (specifically semaglutide and liraglutide) reduce Major Adverse Cardiovascular Events (MACE) by 12-26% in patients with type 2 diabetes and obesity.
If you have type 2 diabetes and obesity, ask your doctor about the heart benefits of GLP-1 drugs. They can significantly reduce your risk of heart attacks and strokes, independent of weight loss.
StrongSupportsVERY_HIGH confidence
Semaglutide (SUSTAIN-6): –26% (HR 0.74); Liraglutide (LEADER): –13% (HR 0.87)
Why this rating
Based on dedicated Cardiovascular Outcome Trials (CVOTs).
Source
GLP-1 and GIP analogues in the treatment of obesity – Current State of Knowledge
Marta Grycan et al. · Biuletyn Głównej Biblioteki Lekarskiej · 2025
DOI 10.2478/bgbl-2025-0015
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dual GLP-1/GIP agonist tirzepatide (10-15 mg/week) produces superior weight loss (approx. 20.2%) compared to semaglutide (2.4 mg/week, approx. 13.7%) in patients with obesity.Strong
- Discontinuation of GLP-1/GIP agonist therapy leads to significant weight regain (approx. 2/3 of lost weight within 1-2 years), necessitating chronic use.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →